H. Lundbeck A/S

H. Lundbeck A/S, commonly known as Lundbeck, is a Danish international pharmaceutical company specializing in the research, development, manufacturing, marketing, and sale of innovative therapies for brain diseases. Its portfolio targets disorders such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, and epilepsy, with key products including Rexulti, Abilify Maintena, Abilify Asimtufii, Vyepti, Brintellix, and others that reach millions of patients worldwide. Founded in 1915 by Hans Lundbeck in Copenhagen and headquartered in Valby, Denmark, the company employs approximately 5,300 to 5,700 people across more than 50 countries, with production facilities in Denmark, France, and Italy, and research centers in Denmark, the US, and Asia. Lundbeck's strategic focus on central nervous system disorders has driven over 70 years of neuroscience expertise, resulting in more than 30 treatments launched globally and registration in over 100 countries. The Lundbeck Foundation, holding about 70% of shares, supports high-quality medical research. In 2025, the company reported revenues exceeding DKK 24.6 billion, primarily from strategic brands, underscoring its significant role in advancing brain health therapies.